Moderna chief celebrates breakthrough melanoma mRNA vaccine in Madrid
Moderna CEO Stéphane Bancel said the Phase 3 trial of the mRNA melanoma therapy intismeran met its primary goals at the ESMO meeting in Madrid.
During the European Society for Medical Oncology meeting in Madrid, Moderna’s chief executive Stéphane Bancel reported that intismeran, the company’s customized mRNA therapy for melanoma, achieved its primary endpoints in a Phase 3 trial. The drug, created in partnership with Merck, represents ten years of development and counters earlier skepticism about cancer vaccines. Bancel described the outcome as a milestone for both patients and the scientific community.
He indicated that the success will influence Moderna’s broader R&D pipeline and may affect its strategic direction. The announcement came on a sunny Saturday, underscoring the significance of the moment for the firm’s leadership.
Why it matters
A successful melanoma vaccine could change cancer treatment and boost Moderna's position in oncology.
How this story developed
- Oct 22 Moderna and Merck shares tumble after unverified vaccine details surface on X
- Oct 23 Shares of Moderna and Merck fell sharply after unverified vaccine details were posted on X.
- Oct 24 Results are slated for presentation at the ESMO conference and have been approved for publication in NEJM.
In this story
Related stories
5 in this thread